Lonza Specialty Ingredients
(Bain Capital & Cinven)

Our Approach

  • We offer highly tailored and relevant buyside support and advice
  • We leverage off an extensive global network built over two decades
  • We evaluate buy-and-build potential offering global access through Mergers Alliance

We employed these capabilities when we advised Bain Capital and Cinven on their CHF 4.2bn joint acquisition of Lonza’s Specialty Ingredients business.


Chemicals & Ingredients
Bain Capital
Lonza Group

Public or Private: Public

Client Position: Buyer

  • Company Profile
  • Transaction Background

Bain Capital and Cinven are global Private Equity firms, both with substantial experience and expertise within the chemical sector.

The target, Lonza’s Specialty Ingredients business, is a provider of specialty chemicals for microbial control solutions based at a production facility in Switzerland. Its products are used in disinfectants, preservatives, personal care products, coatings and other industrial applications.

  • Lonza launched a competitive auction of its Specialty Ingredients business in 2020
  • In particular, Opus assisted its clients on their evaluation of Lonza Specialty Ingredients as a platform for consolidation within the highly attractive microbial control sector